NIHS特別講演会(殿町♯8)

Research conducted by US FDA/NCTR's Division of Genetic and Molecular Toxicology



題

演



Dr. Heflich received a Ph.D. in Microbiology from Rutgers-The State University of New Jersey in 1976, followed by postdoctoral training with Veronica Maher and Justin McCormick at Michigan State University. He joined the U.S. FDA's National Center for Toxicological Research in 1979.

2013~, Director, Division of Genetic and Molecular Toxicology, NCTR, U.S. FDA.

他、Environmental and Molecular and Mutagenesis誌 の編集委員長を歴任、米国環境 変異原学会のAlexander Hollaender Awardを受賞、書 籍、原著論文等、250篇以上の 著作。Pig-a遺伝子変異試験の OECDガイドライン化へ代表と して尽力中。

Dr. Robert H. Heflich

Director, Division of Genetic and Molecular Toxicology, NCTR, U.S. Food and Drug Administration

要旨

The Division of Genetic and Molecular Toxicology (DGMT) dates back nearly 50 years, to the founding of the U.S. Food and Drug Administration's National Center for Toxicological Research (USFDA/NCTR) in 1972. The DGMT presently has 33 employees, 12 of whom are Principle Investigators. The Mission of the DGMT is to 'Improve public health by providing FDA with the expertise and tools necessary for comprehensive assessment of genetic risk and by strengthening approaches to integrate knowledge of genetic risk into regulatory decision making'. In addressing its mission, DGMT conducts a variety of research projects requested by regulators from the FDA Product Centers. These could involve small projects, such as performing in vitro testing on a suspected drug impurity, to large multi-year projects, such as gaining regulatory acceptance for the in vivo Pig-a gene mutation assay or developing an in vitro organotypic airway model for evaluating the toxicity of inhaled substances. DGMT scientists also are exploring ways of using errorcorrected next generation sequencing to evaluate the genetic toxicity of difficult-to-evaluate FDA-regulated substances, such as nanomaterials, and off-target sequence changes caused by gene Although genetic toxicity data have been used by FDA editing. regulators for many years, advances in the science, improvements in testing methods, and new products continue to make work done by the DGMT an important part of FDA's research portfolio.

日時 2019年6月17日(月) 14:00~15:00 開場13:30 国立医薬品食品衛生研究所 2階共用会議室

【お問い合わせ先】 国立医薬品食品衛生研究所 変異遺伝部 堀端 克良 電話:044-270-6600内3031 メール:horibata@nihs.go.jp